U.S. Chamber of Commerce Global Innovation Policy Center

11/17/2026 | Press release | Distributed by Public on 11/17/2026 09:38

The 'Evergreening' Myth: Defending American IP

The "Evergreening" Myth: Defending American IP

A new report shows claims that drug companies abuse the patent system to block cheaper generics are based on misleading data, not reality-and lawmakers risk writing bad policy if they fall for it.

John Manchester

Director, IP Policy, Global Innovation Policy Center (GIPC), U.S. Chamber of Commerce

Published

November 17, 2026

Share

A new Hudson Institute report by George Mason University Law Professor Adam Mossoff dismantles the narrative that biopharmaceutical companies are artificially extending patent monopolies. Mossoff's research examines the data used by critics, such as the group I-MAK, who accuse pharmaceutical companies of "evergreening"-extending their monopolies by building "patent thickets," or dense webs of overlapping patents on minor drug modifications, to delay cheaper generic alternatives. He concludes that these groups manufacture the illusion of endless monopolies by artificially inflating patent counts, often factoring in abandoned applications, pending applications, and entirely unrelated patents.

Despite claims that pharmaceutical companies use serial patenting to extend their monopolies indefinitely, the reality is quite different. Actual periods of market exclusivity have remained relatively stable over the last several decades, averaging about 13 to 14 years. Furthermore, a 2024 U.S. Patent and Trademark Office study validated this by finding that simply counting the number of patents associated with a product is an unreliable way to predict when generic competition will actually occur.

What critics frequently dismiss as "evergreening" often represents genuine, ongoing innovation. Many of the additional patents filed after a drug's initial approval protect subsequent advancements, such as new formulations, improved delivery mechanisms, more efficient manufacturing processes, or newly discovered therapeutic uses that provide meaningful benefits to patients.

Unfortunately, flawed data is increasingly infecting congressional debates and legislative proposals. Relying on inflated statistics risks pushing policymakers toward reforms based on an inaccurate understanding of how the patent system works. For instance, the U.S. Chamber of Commerce recently opposed the Eliminating Thickets to Increase Competition (ETHIC) Act, warning that the legislation would weaken patent rights based on the misguided assumption that large patent portfolios are inherently problematic.

Ultimately, the debate over pharmaceutical patenting should be driven by evidence, not manufactured patent counts. Relying on outcome-driven data feeds an anti-IP narrative that threatens to erode the foundational property rights driving American innovation. Before adopting reforms that weaken patent protections, policymakers must ensure they are addressing real problems rather than chasing statistical myths, so they do not chill the critical investments required to bring new, life-saving treatments to patients.

About the author

John Manchester

U.S. Chamber of Commerce Global Innovation Policy Center published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 17, 2026 at 15:38 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]